cb 10375 has been researched along with Vomiting in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abel, G; Ashley, SE; Cairnduff, F; Calvert, AH; Evans, BD; Graham, MA; Gumbrell, LA; Judson, IR; Rutty, CJ; Wilman, DE | 1 |
| Bermudez, J; Boyle, EA; Miner, WD; Sanger, GJ | 1 |
1 trial(s) available for cb 10375 and Vomiting
| Article | Year |
|---|---|
Phase I trial and pharmacokinetics of trimelamol (N2,N4,N6-trihydroxymethyl-N2,N4,N6-trimethylmelamine).
Topics: Adult; Aged; Antineoplastic Agents; Clinical Trials as Topic; Drug Administration Schedule; Drug Evaluation; Female; Humans; Leukopenia; Male; Middle Aged; Nausea; Neoplasms; Ovarian Neoplasms; Triazines; Vomiting | 1989 |
1 other study(ies) available for cb 10375 and Vomiting
| Article | Year |
|---|---|
The anti-emetic potential of the 5-hydroxytryptamine3 receptor antagonist BRL 43694.
Topics: Animals; Apomorphine; Cisplatin; Cyclophosphamide; Dogs; Doxorubicin; Ferrets; Granisetron; Indazoles; Male; Pyrazoles; Triazines; Vomiting; Whole-Body Irradiation | 1988 |